WFA
ACAD icon

Wipfli Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Wipfli Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$33K Buy
+2,009
New +$32.5K ﹤0.01% 1314

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wipfli Financial Advisors's ACAD Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2022: 2,009 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #1314 among its holdings.

223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • Wipfli Financial Advisors held 2,009 shares of Acadia Pharmaceuticals worth $33K as of Q3 2022.
  • Acadia Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
  • Acadia Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1314 holding.
  • 223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.